Therapy Acceleration Program

A strategic initiative to accelerate the development of innovative blood cancer treatments, supportive care and diagnostics.

The Therapy Acceleration Program® (TAP) identifies and funds innovative projects related to therapies, supportive care or diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.

TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain the resources they need or a partner to complete the testing, registration and marketing of new treatments, supportive care and diagnostics for leukemia, lymphoma and myeloma.

TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and each approved project is closely monitored by TAP staff. 

Latest News

  • Valor Biotherapeutics, LLC, (Valor) and The Leukemia & Lymphoma Society (LLS) announced on August 6 2015 that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for Valor’s lead product candidate, IGN002. The approved IND is a key step in allowing Valor—a joint venture between ImmunGene and Caliber Biotherapeutics—to begin a phase 1 clinical study of IGN002 in patients with non-Hodgkin lymphoma (NHL). Through its Therapy Acceleration Program (TAP), a strategic initiative to partner with biotechnology companies and speed the development of new therapies, LLS previously committed approximately $6 million to co-fund the pre-clinical development, manufacturing, and a Phase 1 clinical study of IGN002. Valor, ImmunGene, and LLS staff have collaborated over the past two years to complete the pre-clinical development and manufacturing of IGN002 for the IND filing.

  • The Leukemia & Lymphoma Society (LLS) and Kite Pharma, Inc., announced on July 1 2015 that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Under the collaboration, LLS will launch a broad scope educational program focusing on CAR T-cell therapy for the treatment of blood cancers, as well as support outreach for clinical trial enrollment. LLS also will contribute up to $2.5 million, through the Therapy Acceleration Program®, to help fund Kite's ongoing Phase 1/2 clinical study of KTE-C19 (NCT02348216).

  • Celator Pharmaceuticals, Inc. released induction response data, a secondary endpoint, which indicated its drug, CPX-351, performed better than the current standard therapy known as 7+3 (conventional cytarabine and daunorubicin). A relative improvement in response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen) was found, which is in line with two other previous Phase II trials with CPX-351. Data reflecting the primary endpoint of the study, overall survival, is expected in the first quarter of 2016. Since response rate can be an important prognostic indicator of overall survival and clinical benefit, the new data is very encouraging. The study (NCT01696084) was sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program®.

  • Curis, Inc. announced results from the completed dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907 (NCT01742988) at the 2015 ASCO Annual Meeting. At the recommended Phase 2 dose and schedule, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) and Hodgkin's lymphoma (HL). Two complete responses (CRs) and 4 partial responses (PRs) were reported in 10 response evaluable patients with DLBCL, including 3 responses (1 CR and 2 PRs) in patients with transformed follicular lymphoma (t-FL/DLBCL), a very difficult to treat subset of DLBCL. One patient with HL experienced partial response out of a total of 12 response evaluable patients with HL. In addition, stable disease (SD) has been observed in 25 of 44 response evaluable patients across various lymphomas and multiple myeloma (MM). The development of CUDC-907 is in part supported by The Leukemia & Lymphoma Society's Therapy Acceleration Program®.

  • Stemline Therapeutics, Inc. announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). These results demonstrate an acceptable safety profile, with no cumulative side effects observed after multiple cycles of SL-401 administered at dose levels up to 12 ug/kg/day. Three out of five BPDCN patients treated at the 12 ug/kg/day dose achieved major responses to date, including complete responses (CRs). Stemline intends to continue to enroll BPDCN patients in this ongoing pivotal trial at the 12 ug/kg/day dose level. The study (NCT02113982) is sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program®.

  • Affimed has initiated a phase 2a clinical trial (NCT02321592) in Hodgkin lymphoma, or HL for its lead candidate, AFM13, a bispecific CD30/CD16A TandAb antibody, with first data expected in late 2015 and final data expected in the second half of 2016. Affimed is preparing an additional phase 1b/2a investigator-initiated trial with AFM13 in CD30-positive lymphoma as well as a phase 1b trial with AFM13 in combination with a checkpoint modulator. Initial evidence of the synergistic effect of AFM13 in combination with checkpoint modulators was presented at the ASCO 2015 Annual Meeting.

  • arGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, announced an alliance in which they will collaborate to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. The development of ARGX-110, an antibody that binds CD70, is being supported in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program®.

  • OXiGENE, Inc. a biopharmaceutical company developing novel therapies for the treatment of cancer, announced that the U.S. Patent and Trademark Office has granted it a patent (U.S. Patent No. 9,040,500) related to the use of OXi4503 for the treatment of myeloid neoplasms, including acute myeloid leukemia (AML). The study (NCT01085656) is sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program® and is being led by Dr. Chris Cogle at the University of Florida.

  • Acetylon Pharmaceuticals Inc. initiated a Phase 1a/b study of ACY-241 in combination with Pomalyst® in relapsed or relapsed-and-refractory multiple myeloma (NCT02400242). Acetylon also presented data on the synergistic activity of selective HDAC6 inhibition in preclinical models of multiple myeloma and mantle cell lymphoma at the AACR 2015 Annual Meeting.

  • Researchers at Johns Hopkins announced significant findings in Science Translational Medicine about a novel approach to immunotherapy to treat patients with myeloma. A Phase 2 study (NCT01858558) is currently enrolling and is being supported through the Therapy Acceleration Program®

  • Nanosyn and The Leukemia & Lymphoma Society Announce Achieving a Significant Milestone in Developing New Therapies for MLL Leukemia

  • Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan

Clinical Trials in Partnership with LLS

Both TAP and LLS research grant fundings are critical in supporting many active clinical trials at any given time. The website provides an updated listing of clinical trials where LLS is listed as a collaborator. is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. More information about the clinical trials in partnership with LLS TAP can also be found within each TAP division found below.

How TAP Works

The program comprises three divisions, each with designated strategies, to speed the development of blood cancer treatments, supportive care and diagnostics:

TAP Divisions

Academic Concierge Division

The Academic Concierge Division capitalizes on LLS's academic grant-supported portfolio of development-stage projects. This division supports the further development of selected academic projects (with or without prior LLS grant support) to gain clinical proof of concept. Successful projects will potentially be advanced for further clinical development by creating additional partnerships with pharmaceutical...

Biotechnology Accelerator Division

The Biotechnology Accelerator Division identifies companies developing novel anti-cancer therapies, supportive care or diagnostics and co-funds specific projects that will enable a company to partner or raise additional funding to complete the testing, registration and marketing of new therapies or diagnostics for blood cancer indications. TAP funding is different from the traditional grant at ...

Clinical Trials Division

The Clinical Trials Division was created to help patients gain easier access to clinical trials in the community and familiar settings and to address the bottleneck of clinical trials – patient enrollment rate. In June 2013 the Blood Cancer Research Partnership (BCRP) was established together with the Dana-Farber Cancer Institute in Boston with TAP funding. BCRP aims to accelerate the advancemen...